Coronary Artery Perforation: Difference between revisions
New page: {{SI}} {{WikiDoc Cardiology Network Infobox}} {{CMG}}<br/> '''Associate Editors-In-Chief:''' Xin Yang, M.D.; Duane Pinto, M.D.; Brian C. Bigelow, M.D. ==Background== Coronary perforation ... |
No edit summary |
||
| Line 32: | Line 32: | ||
==Treatment== | ==Treatment== | ||
Many different treatment options exist. First, the reversal of [[anticoatulation]] can be accomplished with [[Protamine]] if the patient is on [[heparin]] (guided by activated clotting time), or through [[platelet]] [[transfusions]] (4-10 units) if the patient was given [[abciximab]] or [[thienopyridine]]. Prolonged balloon inflation may be another treatment option. Immediate occlusion of the perforated vessel at the perforation site for 10 minutes at 2-4 [[atms]]. If there is continued evidence of perforation, use perfusion balloons if available to allow for prolonged inflation without inducing myocardial [[ischemia]]. | Many different treatment options exist. First, the reversal of [[anticoatulation]] can be accomplished with [[Protamine]] if the patient is on [[heparin]] (guided by activated clotting time), or through [[platelet]] [[transfusions]] (4-10 units) if the patient was given [[abciximab]] or [[thienopyridine]]. | ||
Prolonged balloon inflation may be another treatment option. Immediate occlusion of the perforated vessel at the perforation site for 10 minutes at 2-4 [[atms]]. If there is continued evidence of perforation, use perfusion balloons if available to allow for prolonged inflation without inducing myocardial [[ischemia]]. | |||
[[Polytetrafluoroethylene|Polytetrafluoroethylene (PTFE)]] covered stents (Jomed stent)<ref name="pmid15084537">{{cite journal |author=Fineschi M, Gori T, Sinicropi G, Bravi A |title=Polytetrafluoroethylene (PTFE) covered stents for the treatment of coronary artery aneurysms |journal=Heart |volume=90 |issue=5 |pages=490 |year=2004 |month=May |pmid=15084537 |pmc=1768192 |doi= |url=}}</ref> can seal the perforation site. However, the stent is bulky and can be difficult to deploy. To decrease timing between deflation of balloon and deployment of the stent, bilateral groin access with two guide catheters approach should be considered. | |||
==References== | ==References== | ||
Revision as of 16:41, 29 July 2010
| Cardiology Network |
 Discuss Coronary Artery Perforation further in the WikiDoc Cardiology Network |
| Adult Congenital |
|---|
| Biomarkers |
| Cardiac Rehabilitation |
| Congestive Heart Failure |
| CT Angiography |
| Echocardiography |
| Electrophysiology |
| Cardiology General |
| Genetics |
| Health Economics |
| Hypertension |
| Interventional Cardiology |
| MRI |
| Nuclear Cardiology |
| Peripheral Arterial Disease |
| Prevention |
| Public Policy |
| Pulmonary Embolism |
| Stable Angina |
| Valvular Heart Disease |
| Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Associate Editors-In-Chief: Xin Yang, M.D.; Duane Pinto, M.D.; Brian C. Bigelow, M.D.
Background
Coronary perforation occurs when a dissection or an intimal tear is so severe that it extends outward sufficiently to completely penetrate the arterial wall. It is an uncommon complication of coronary intervention, with an incidence of 0.19%-0.58%[1][2][3], as noted among various studies. However, it is associated with significant morbidity and mortality. One study found a 12.6% incidence of acute myocardial infarction, 11.6% incidence of cardiac tamponade and a mortality rate of 7.4%[2].
Associations with coronary perforation include:
- Balloon to artery ratio > 1.1
- Use of debulking procedure
- Complex coronary anatomy (i.e. calcified lesion, chronic total occlusion, tortuosity of the vessel and ostial lesion)
- Stiff and hydrophilic wires
Classification
The Ellis Classification[4] categorizes coronary artery perforations based on their angiographic appearance in the following manner:
- Type I - Extraluminal crater without extravasation
- Type II - Epicardial fat or myocardial blush without contrast jet extravasation
- Type III - Extravasation through frank (> 1 mm) perforation
- Type III "cavity spilling" (CS) - Refers to Type III perforations with contrast spilling directly into either the left ventricle, coronary sinus or other anatomic circulatory chamber
The Ellis Classification was evaluated as a predictor of certain outcomes and as a basis for management. Stratifying the outcomes by perforation type are summarized as follows[4]:
- Type I - No deaths or myocardial infarction, tamponade incidence 8%
- Type II - No deaths, myocardial infarction incidence 14%, tamponade incidence 13%
- Type III - Mortality incidence 19%, cardiac tamponade incidence 63%, the need for urgent bypass surgery 63%
- Type III "cavity spilling" (CS) - No deaths, myocardial infarction or tamponade, but sample limited in size
Goals of Treatment
There are several goals involved in treating perforations. Prevention of complications such as tamponade, myocardial infarction (MI) and death is critical. It is important to maintain hemodynamic stability. Should tamponade occur, it is important to detect and treat it immediately. Additionally, a goal of treatment is to decrease the need for emergent bypass surgery.
Treatment
Many different treatment options exist. First, the reversal of anticoatulation can be accomplished with Protamine if the patient is on heparin (guided by activated clotting time), or through platelet transfusions (4-10 units) if the patient was given abciximab or thienopyridine.
Prolonged balloon inflation may be another treatment option. Immediate occlusion of the perforated vessel at the perforation site for 10 minutes at 2-4 atms. If there is continued evidence of perforation, use perfusion balloons if available to allow for prolonged inflation without inducing myocardial ischemia.
Polytetrafluoroethylene (PTFE) covered stents (Jomed stent)[5] can seal the perforation site. However, the stent is bulky and can be difficult to deploy. To decrease timing between deflation of balloon and deployment of the stent, bilateral groin access with two guide catheters approach should be considered.
References
- ↑ Javaid A, Buch AN, Satler LF; et al. (2006). "Management and outcomes of coronary artery perforation during percutaneous coronary intervention". Am. J. Cardiol. 98 (7): 911–4. doi:10.1016/j.amjcard.2006.04.032. PMID 16996872. Unknown parameter
|month=ignored (help) - ↑ 2.0 2.1 Fasseas P, Orford JL, Panetta CJ; et al. (2004). "Incidence, correlates, management, and clinical outcome of coronary perforation: analysis of 16,298 procedures". Am. Heart J. 147 (1): 140–5. PMID 14691432. Unknown parameter
|month=ignored (help) - ↑ Dippel EJ, Kereiakes DJ, Tramuta DA; et al. (2001). "Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: an algorithm for percutaneous management". Catheter Cardiovasc Interv. 52 (3): 279–86. doi:10.1002/ccd.1065. PMID 11246236. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 Ellis SG, Ajluni S, Arnold AZ; et al. (1994). "Increased coronary perforation in the new device era. Incidence, classification, management, and outcome". Circulation. 90 (6): 2725–30. PMID 7994814. Unknown parameter
|month=ignored (help) - ↑ Fineschi M, Gori T, Sinicropi G, Bravi A (2004). "Polytetrafluoroethylene (PTFE) covered stents for the treatment of coronary artery aneurysms". Heart. 90 (5): 490. PMC 1768192. PMID 15084537. Unknown parameter
|month=ignored (help)